Safety and Efficacy of Enoxaparin in Percutaneous Coronary Intervention Patients
Posted on: Tuesday, 6 September 2005, 16:23 CDT
Results of the STEEPLE trial to be announced at the Hotline session today by Pr Gilles Montalescot, the trial's principal investigator, have the potential to revise current procedural anticoagulation using standard uncertain ACT-driven unfractionated heparin (UFH) in percutaneous coronary intervention (PCI). STEEPLE (Safety and efficacy of enoxaparin in elective percutaneous coronary intervention: an international randomized evaluation) is the first large scale, prospective, open label, randomized, controlled clinical trial comparing intravenous (iv) enoxaparin and UFH in the catheterization laboratory.
The study was conducted with 3,528 patients from 124 sites and nine countries in Europe, North America and Australasia undergoing non emergent PCI randomized to iv enoxaparin (0.5 mg/kg or 0.75 mg/kg) or an activated clotting time (ACT)-adjusted UFH regimen, stratified by the operator's choice of glycoprotein (GP) IIb/IIIa inhibitor use. The primary endpoint was to evaluate the safety of iv enoxaparin compared with iv UFH measuring the incidence of non-coronary artery bypass graft (CABG)-related major and minor bleeding up to 48 hours following index PCI. The main secondary efficacy endpoint was the percentage of patients reaching target anticoagulation levels at the beginning and end of the procedure. A secondary efficacy composite endpoint consisted of non-CABG-major bleeding up to 48 hours, all cause mortality, non-fatal myocardial infarction, or urgent target vessel revascularization at 30 days. The data may confirm earlier results from small and non comparative trials that have shown enoxaparin to be simple and effective and not associated with excessive bleeding in patients undergoing PCI with or without GP IIb/IIIa inhibitors.1
On the World Wide Web:
European Society of Cardiology
Related Articles
- Living Cell Technologies Reports Clinical Benefit for All Patients in Diabetes Trial
- Over 135 Patients Randomized in Airway Bypass Trial for Emphysema
- KRAS Gene Status May Impact Vectibix(TM) (Panitumumab) Efficacy and Patient Reported Outcomes in Advanced Colorectal Cancer Patients
- Top-Line Efficacy Data Presented From Phase 2 Trial of Alemtuzumab in Multiple Sclerosis
- ZIOPHARM Treats Patients in U.S. Phase I Trials of Oral Darinaparsin and Indibulin
- Harvest Technologies Announces FDA Approval to Begin the First Randomized, Placebo-Controlled Clinical Trial in the United States Using Autologous Adult Stem Cells to Treat Patients With End-Stage Critical Limb Ischemia
- Dyax Corp. Treats First Patient in Phase 2 Trial for On-Pump Cardiothoracic Surgery
- FDA Approves Expansion of Angiomax(R) (Bivalirudin) Label to Include Patients With or at Risk of HIT/HITTS Undergoing PCI; HIT/HITTS Places Patients at Higher Risk of Life-Threatening Complications
- Antigenics Announces Preliminary Survival Data From Its Randomized Phase 3 Metastatic Melanoma Trial
- Genmab A/S and Medarex Announce Positive Safety and Efficacy Data in Phase I/II Trial With HuMax-Inflam/MDX-018
 |
 |
User Comments (0)
RSS Feeds